首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1622078

全球神經營養性角膜炎治療市場規模（按治療、地區、範圍和預測）

Global Neurotrophic Keratitis Treatment Market Size By Treatment, By Competitive Landscape, By Geographic Scope And Forecast

出版日期: 2024年08月23日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

神經營養性角膜炎治療市場規模及預測

神經營養性角膜炎治療市場規模預計在 2023 年達到 44 億美元，到 2030 年將達到 88.1 億美元，2024 年至 2030 年的複合年增長率為 7.2%。

全球神經營養性角膜炎治療市場的市場推動因素

神經營養性角膜炎治療市場的市場推動因素可能受到多種因素的影響。

神經營養性角膜炎發生率不斷上升：一個重要因素是神經營養性角膜炎發生率不斷上升，其發病原因包括糖尿病、帶狀皰疹、術後困難等，常與疾病相關。人口老化也是導致盛行率上升的原因之一，因為老年人更容易患上這些潛在疾病。

診斷進展：

診斷技術的進步使得能夠早期準確地識別神經營養性角膜炎，增加了對治療方案的需求。生物標誌物的發現和影像技術的改進有助於改善疾病管理。

創造創新治療方法：

由於重組人類神經生長因子（cenegermin）等新型治療劑和尖端治療方法的發展，市場正在不斷擴大。這些創新治療方法更具針對性和更有效，可能會改善患者的治療效果。

提高知識和敏感度：

隨著患者和醫療保健專業人員對神經營養性角膜炎及其可用治療方法的瞭解不斷增加，市場正在擴大。教育工作和越來越多的研究論文正在提高人們對該疾病的認識和理解。

科學技術研究補助金：

新療法的發現得益於製藥公司和學術機構對研發的大量投資。這帶來了大量潛在治療方法，促進了市場擴張。

監理機關的批准與支持：

良好的監管環境有利於市場擴張，FDA 和 EMA 批准了新療法。此外，對於加速審查程序和孤兒藥指定的監管支援也很有利。

創新：

藥物傳遞技術的發展，例如緩釋製劑和基於奈米技術的方法，正在提高治療神經營養性角膜炎的便利性和有效性，有助於擴大市場。

醫療費用不斷增加：

政府和企業對醫療保健的資助提高了獲得尖端神經營養性角膜炎治療的機會。此外，報銷指南的改善和醫療保健基礎設施的發展也在推動市場擴張。

增加微創手術的使用：

對於侵入性較小、恢復時間較短、併發症風險較低的治療的需求正在對市場產生積極影響。使用這些技術治療神經營養性角膜炎正在獲得認可。

合作夥伴關係和協作：神經營養性角膜炎治療的創新由研究機構、製藥公司和醫療保健提供者之間的策略聯盟和夥伴關係推動。這類合作的目標通常是為了加速新療法的發現和行銷。

限制全球神經營養性角膜炎治療市場的因素

有幾個因素可能會對神經營養性角膜炎治療市場造成市場限制和課題。這些包括：

高昂的醫療費用：

手術和重組人類神經生長因子 (rhNGF) 等最先進的治療方法對於治療神經營養性角膜炎的費用非常昂貴。患者可能會發現難以獲得這種治療，特別是在沒有全民健保的地區。

知識與診斷不足：

由於神經營養性角膜炎是一種罕見疾病，患者和醫護人員往往缺乏對它的知識。這可能會導致誤診或漏診，減少接受適當治療的患者數量。

監理課題：

獲得監管機構批准的新療法成本高且耗時。由於 FDA 和 EMA 等組織實施的嚴格監管，新療法進入市場可能需要一些時間。

替代療法的可用性：

更多平價的替代品（如傳統眼藥水、藥膏和自體血清眼藥水）的出現，可能會減少對更昂貴和更先進的治療的需求。某些醫療專業人士和患者可能會更喜歡這些較便宜的選擇。

安全性問題與副作用：

由於不良副作用，患者可能會拒絕接受某些 NK 療法。在獲得長期安全性和有效性的證據之前，安全問題可能會阻礙新療法的採用。

保險和報銷問題：

NK 治療的保險覆蓋範圍各不相同，有些治療根本不包括在內。這可能會導致患者自付費用增加，並進一步限制獲得有效治療的機會。

有限的研究與發展：

與更常見的疾病相比，這種疾病的罕見性意味著正在進行的研究和開發相對較少。這可能會阻礙新療法的開發和現有療法的進展。

經濟阻礙因素：

在中低收入國家，財政限制會嚴重限制人們獲得尖端 NK 治療的機會。這些地區的醫療保健基礎設施不足可能會阻礙先進藥物的廣泛普及和使用。

病人依從性：

NK 治療通常需要嚴格遵守藥物治療，這對患者來說可能很困難。缺乏依從性可能導致治療結果不理想且治療效果被低估。

缺乏專業照護：

神經營養性角膜炎的治療通常需要有治療角膜疾病經驗的眼科醫師的服務。專家的短缺是提供優質醫療服務的一大障礙，尤其是在貧困的農村地區。

The market drivers for the Neurotrophic Keratitis Treatment Market can be influenced by various factors. These may include: Rising Neurotrophic Keratitis Prevalence: One important factor is the increasing prevalence of neurotrophic keratitis, which is frequently linked to diseases including diabetes, herpes zoster, and difficulties following surgery. Because older people are more susceptible to these underlying illnesses, an ageing population also plays a role in the rising prevalence.

Progress in Diagnostic Methods:

The need for treatment options is increasing due to advancements in diagnostic techniques that enable early and accurate identification of neurotrophic keratitis. Improved biomarker discovery and imaging technologies are contributing to improved disease management.

Creation of Innovative Treatments:

The market is growing due to the development of novel therapeutic drugs and cutting-edge treatments such recombinant human nerve growth factor (cenegermin). Better patient outcomes are possible thanks to these innovative treatments, which offer more focused and efficient methods.

Enhanced Knowledge and Sensitization:

The market is expanding as a result of patients' and healthcare professionals' increasing knowledge of neurotrophic keratitis and available treatments. More awareness and comprehension of the illness are being fostered by educational initiatives and an increase in research publications.

Expenditure on Scientific and Technological Research:

The identification of new treatment modalities is being facilitated by large investments made in research and development by pharmaceutical corporations and academic institutions. This is creating a strong pipeline of possible treatments and driving market expansion.

Regulatory Acceptance and Assistance:

Market expansion is being aided by favourable regulatory environments and the FDA and EMA approving novel therapies. Accelerated review procedures and regulatory assistance for orphan drug status are also advantageous.

Innovations in Technology:

Technological developments in medication delivery, like sustained-release formulations and nanotechnology-based methods, are improving the convenience and effectiveness of treatments for neurotrophic keratitis, which is propelling the market's expansion.

Increasing Costs of Healthcare:

Government and business sector funding on healthcare is improving access to cutting-edge neurotrophic keratitis treatments. Further fostering market expansion are better reimbursement guidelines and healthcare infrastructure.

Expanding Use of Procedures With Minimal Invasiveness:

The market is being positively impacted by the desire for less intrusive treatment choices that have shorter recovery times and a lower risk of consequences. The use of these techniques to treat neurotrophic keratitis is growing in acceptance.

Partnerships & Cooperations: Innovation in neurotrophic keratitis treatments is being propelled by strategic alliances and partnerships among research organisations, pharmaceutical businesses, and healthcare providers. The goal of these partnerships is frequently to hasten the creation and marketing of novel treatments.

Global Neurotrophic Keratitis Treatment Market Restraints

Several factors can act as restraints or challenges for the Neurotrophic Keratitis Treatment Market. These may include:

Exorbitant Treatment Costs:

Surgical procedures and cutting-edge therapy options, such as recombinant human nerve growth factor (rhNGF), can be highly costly for treating neurotrophic keratitis. Patients may find this to be less accessible, particularly in areas without universal healthcare.

Insufficient Knowledge and Diagnosis:

Since neurotrophic keratitis is an uncommon condition, both patients and medical professionals frequently lack knowledge about it. This may result in an incorrect or underdiagnosis, which would decrease the number of patients receiving the right care.

Regulatory Difficulties:

Getting novel treatments approved by the authorities can be an expensive and time-consuming procedure. New treatments may take longer to reach the market due to the strict regulations imposed by organisations like the FDA and EMA.

Availability of Alternative therapies:

The demand for more expensive, more advanced therapies may decline if there are more affordable alternatives available, such as traditional eye drops, ointments, and autologous serum eye drops. These less expensive options may be preferred by certain healthcare professionals and patients.

Safety concerns and adverse effects:

Patients may be discouraged from taking certain NK therapies because to their unpleasant side effects. Adoption of novel therapies may be hindered by safety concerns until long-term safety and efficacy evidence become available.

Insurance and Reimbursement Issues:

There might be variability in insurance coverage for NK treatments, with certain treatments not receiving any coverage at all. Patients may incur significant out-of-pocket costs as a result, further restricting their access to efficacious treatments.

Limited Research and Development:

Compared to more prevalent illnesses, there is comparatively less research and development activity because of the disease's rarity. This may impede the development of novel therapies and the advancement of current ones.

Economic Restrictions:

In low- and middle-income nations, financial restrictions may severely restrict access to cutting-edge NK treatments. The broad availability and usage of sophisticated medicines may be hindered by the inadequate healthcare infrastructure in these locations.

Patient Compliance:

Strict adherence to pharmaceutical regimens is often necessary for NK treatments, which might provide difficulties for patients. Non-compliance may result in less than ideal treatment results, which lowers the therapies' perceived efficacy.

Lack of Specialist Care:

Ophthalmologists with experience treating corneal illnesses are typically needed to treat neurotrophic keratitis. The lack of these specialists can be a major obstacle to providing quality care, particularly in poor and rural locations

Global Neurotrophic Keratitis Treatment Market Segmentation Analysis

The Global Neurotrophic Keratitis Treatment Market is segmented on the basis of Treatment and Geography.

Neurotrophic Keratitis Treatment Market, By Treatment

Topical Antibiotics
Recombinant Human Nerve Growth Factor (rhNGF)
Amniotic Membrane Transplantation
Keratoplasty
Others

Based on Treatment, the market is bifurcated into Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, and Others. The dominance of topical antibiotics in the Neurotrophic Keratitis Treatment Market in the past few years can be attributed to several factors. Topical antibiotics are effective in managing neurotrophic keratitis because they have antimicrobial properties. Neurotrophic keratitis can make the cornea vulnerable to infections, and topical antibiotics help prevent or treat these infections, reducing the risk of complications.

Topical antibiotics have been a conventional and widely used treatment approach for various corneal conditions, including neurotrophic keratitis. Healthcare professionals are familiar with their use, and readily available in numerous formulations, making them a preferred choice for initial treatment. Topical antibiotics often have a broad spectrum of action, targeting many bacteria that may cause corneal infections. This versatility makes them suitable for treating different bacterial infections associated with neurotrophic keratitis. Topical antibiotics are typically administered as eye drops or ointments, making them easy to apply.
Patients can often self-administer these medications at home, which improves treatment compliance and convenience. The neurotrophic keratitis treatment landscape is constantly evolving. Emerging treatment options, such as recombinant human nerve growth factor (rhNGF), amniotic membrane transplantation, and keratoplasty, are gaining attention and showing promising results in clinical studies. While topical antibiotics have been dominant in the past, the market dynamics may shift as newer treatment modalities gain acceptance and demonstrate their efficacy in managing neurotrophic keratitis. Therefore, monitoring the latest developments and research findings is essential to stay updated on the evolving treatment landscape.

Neurotrophic Keratitis Treatment Market, By Geography

North America
Europe
Asia Pacific
Latin America
Middle East and Africa
On the basis of Geography, the Global Neurotrophic Keratitis Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. The Neurotrophic Keratitis Treatment Market has been identified as having high growth potential in the Asia Pacific area. The Asia Pacific region has the largest population, including a growing elderly population. Neurotrophic keratitis is more prevalent among the elderly, and as the population ages over time, the demand for neurotrophic keratitis treatment is expected to increase.
Many major countries in the Asia Pacific region are experiencing rapid economic growth and increasing healthcare expenditure. This provides greater accessibility to healthcare services, including neurotrophic keratitis treatment, and drives market growth. Several other countries in the Asia Pacific region have been investing in improving their healthcare infrastructure. This includes the development of specialized eye care centers, advanced medical facilities, and increased availability of treatment options, which contribute to the growth of the Neurotrophic Keratitis Treatment Market.

Key Players

The major players in the Neurotrophic Keratitis Treatment Market are
Santen Pharmaceutical Co. Ltd.
Novartis AG
RegeneRx
Biopharmaceuticals Inc.
Dompe farmaceutici S.p.A.
Dompe Farma S.r.l.
Horizon Therapeutics plc
AuroLab
Genentech Inc. (a subsidiary of Roche Holding AG)
Johnson & Johnson Services Inc.
Allergan (a subsidiary of AbbVie Inc.

1 INTRODUCTION OF GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET, BY TREATMENT

5.1 Topical Antibiotics
5.2Recombinant Human Nerve Growth Factor (rhNGF)
5.3Amniotic Membrane Transplantation
5.4Keratoplasty
5.5Others

6 GLOBAL EUROTROPHIC KERATITIS TREATMENT MARKET, BY GEOGRAPHY

6.1 Overview
6.2 North America
- 6.2.1 U.S.
- 6.2.2 Canada
- 6.2.3 Mexico
6.3 Europe
- 6.3.1 Germany
- 6.3.2 U.K.
- 6.3.3 France
- 6.3.4 Rest of Europe
6.4 Asia Pacific
- 6.4.1 China
- 6.4.2 Japan
- 6.4.3 India
- 6.4.4 Rest of Asia Pacific
6.5 Rest of the World
- 6.5.1 Latin America
- 6.5.2 Middle East & Africa